Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is 15.61% higher on its value in year-to-date trading and has touched a low of $243.17 and a high of $354.46 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The VRTX stock was last observed hovering at around $333.51 in the last trading session, with the day’s gains setting it 0.34%.
Currently trading at $333.85, the stock is -2.69% and 2.08% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.15 million and changing 0.10% at the moment leaves the stock 9.18% off its SMA200. VRTX registered 24.41% gain for a year compared to 6-month gain of 5.58%. The firm has a 50-day simple moving average (SMA 50) of $8.69 and a 200-day simple moving average (SMA200) of $18.31.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
Sponsored
The stock witnessed a 0.58% loss in the last 1 month and extending the period to 3 months gives it a 14.11%, and is -2.15% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 2.05% over the week and 2.17% over the month.
Vertex Pharmaceuticals Incorporated (VRTX) has around 4800 employees, a market worth around $85.42B and $9.21B in sales. Current P/E ratio is 26.60 and Fwd P/E is 20.68. Profit margin for the company is 35.40%. Distance from 52-week low is 37.29% and -5.81% from its 52-week high. The company has generated returns on investments over the last 12 months (23.60%).
Vertex Pharmaceuticals Incorporated (VRTX) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Vertex Pharmaceuticals Incorporated (VRTX) is a “Overweight”. 31 analysts offering their recommendations for the stock have an average rating of 2.10, where 10 rate it as a Hold and 3 think it is a “Overweight”. 18 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
The EPS is expected to grow by 42.30% this year
Vertex Pharmaceuticals Incorporated (VRTX) Top Institutional Holders
The shares outstanding are 257.40M, and float is at 256.21M with Short Float at 1.26%.
Vertex Pharmaceuticals Incorporated (VRTX) Insider Activity
A total of 230 insider transactions have happened at Vertex Pharmaceuticals Incorporated (VRTX) in the last six months, with sales accounting for 184 and purchases happening 46 times. The most recent transaction is an insider sale by Sanna Bastiano, the company’s EVP, Cell & Genetic Therapies. SEC filings show that Sanna Bastiano sold 2,850 shares of the company’s common stock on May 08 at a price of $350.00 per share for a total of $1.0 million. Following the sale, the insider now owns 32038.0 shares.
Vertex Pharmaceuticals Incorporated disclosed in a document filed with the SEC on May 08 that LEIDEN JEFFREY M (Executive Chairman) sold a total of 1,125 shares of the company’s common stock. The trade occurred on May 08 and was made at $349.00 per share for $0.39 million. Following the transaction, the insider now directly holds 35387.0 shares of the VRTX stock.
Still, SEC filings show that on May 05, LEIDEN JEFFREY M (Executive Chairman) disposed off 879 shares at an average price of $349.56 for $0.31 million. The insider now directly holds 36,512 shares of Vertex Pharmaceuticals Incorporated (VRTX).
Vertex Pharmaceuticals Incorporated (VRTX): Who are the competitors?
The company’s main competitors (and peers) include AbbVie Inc. (ABBV) that is trading -4.65% down over the past 12 months and Krystal Biotech Inc. (KRYS) that is 105.25% higher over the same period. Arcturus Therapeutics Holdings Inc. (ARCT) is 56.23% up on the 1-year trading charts.
